Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

Association between CCND1 and XPC polymorphisms and bladder cancer risk: a meta-analysis based on 15 case–control studies

Authors: Yifei Wang, Zongping Li, Naibo Liu, Guan Zhang

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

Perturbations in cell cycle and DNA repair genes might affect susceptibility to cancer. The aim of this meta-analysis is to generate large-scale evidence to determine the degree to which common Cyclin D1 (CCND1) G870A (dbSNP: rs603965) and xeroderma pigmentosum group C (XPC) Ala499Val (dbSNP: rs2228000) polymorphisms are associated with susceptibility to bladder cancer. The electronic databases PubMed, Embase, Web of Science, and CNKI were searched for relevant studies (with an upper date limit of July 25, 2013). The principal outcome measure for evaluating the strength of association was crude odds ratios (ORs) along with their corresponding confidence intervals (95 %CIs). We found and reviewed nine case–control studies on CCND1 G870A with a total of 6,823 subjects and seven studies on XPC Ala499Val with a total of 7,674 subjects. Our meta-analysis provides evidence that the variant genotype of CCND1 G870A showed a significant association in the occurrence of invasive bladder tumors in former and current smokers. The XPC Ala499Val polymorphism correlated with significant differences between patients and unaffected subjects, but when the groups were stratified by ethnicity, the magnitude of the overall effect was similar only among Caucasian populations. Results from our meta-analysis support the view that the G870A polymorphism may modulate the risk of bladder cancer in conjunction with tobacco smoking and that the Ala499Val polymorphism may contribute to the susceptibility to bladder cancer in Caucasian populations. Our findings, however, warrant larger well-designed studies to investigate the significance of these two polymorphisms as markers of susceptibility to bladder cancer.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Actinomycin C. Cumulative index to IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. IARC Monogr Eval Carcinog Risk Chem Hum. 1986;39:379–403.
3.
Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol. 2007;25:285–95.PubMedCrossRef
4.
Vineis P, Talaska G, Malaveille C, Bartsch H, Martone T, et al. DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int J Cancer. 1996;65:314–6.PubMedCrossRef
5.
Turesky RJ, Freeman JP, Holland RD, Nestorick DM, Miller DW, et al. Identification of aminobiphenyl derivatives in commercial hair dyes. Chem Res Toxicol. 2003;16:1162–73.PubMedCrossRef
6.
Burger MS, Torino JL, Swaminathan S. DNA damage in human transitional cell carcinoma cells after exposure to the proximate metabolite of the bladder carcinogen 4-aminobiphenyl. Environ Mol Mutagen. 2001;38:1–11.PubMedCrossRef
7.
Siraki AG, Chan TS, Galati G, Teng S, O'Brien PJ. N-oxidation of aromatic amines by intracellular oxidases. Drug Metab Rev. 2002;34:549–64.PubMedCrossRef
8.
Wei Q, Spitz MR. The role of DNA repair capacity in susceptibility to lung cancer: a review. Cancer Metastasis Rev. 1997;16:295–307.PubMedCrossRef
9.
Kaufmann WK, Paules RS. DNA damage and cell cycle checkpoints. FASEB J. 1996;10:238–47.PubMed
10.
11.
12.
Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1:22–33.PubMedCrossRef
13.
Tauchi H, Kobayashi J, Morishima K, van Gent DC, Shiraishi T, et al. Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells. Nature. 2002;420:93–8.PubMedCrossRef
14.
Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case–control study. Int J Cancer. 2001;92:562–7.PubMedCrossRef
15.
Wang M, Gu D, Zhang Z, Zhou J. XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis. J Toxicol Environ Health A. 2009;72:698–705.PubMedCrossRef
16.
Li C, Jiang Z, Liu X. XPD Lys(751)Gln and Asp (312)Asn polymorphisms and bladder cancer risk: a meta-analysis. Mol Biol Rep. 2010;37:301–9.PubMedCrossRef
17.
Sun H, Qiao Y, Zhang X, Xu L, Jia X, et al. XRCC3 Thr241Met polymorphism with lung cancer and bladder cancer: a meta-analysis. Cancer Sci. 2010;101:1777–82.PubMedCrossRef
18.
Li F, Li C, Jiang Z, Ma N, Gao X. XRCC3 T241M polymorphism and bladder cancer risk: a meta-analysis. Urology. 2011;77(511):e1–5.
19.
Zhang Y, Wang X, Zhang W, Gong S. An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis. Tumour Biol. 2013;34:973–82.PubMedCrossRef
20.
Dou K, Xu Q, Han X. The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis. Diagn Pathol. 2013;8:112.PubMedCentralPubMedCrossRef
21.
Liu C, Yin Q, Li L, Zhuang YZ, Zu X, et al. APE1 Asp148Glu gene polymorphism and bladder cancer risk: a meta-analysis. Mol Biol Rep. 2013;40:171–6.PubMedCrossRef
22.
Zhang F, Wu JH, Zhao W, Liu HT. XRCC1 polymorphisms increase bladder cancer risk in Asians: a meta-analysis. Tumour Biol. 2013
23.
Wang C, Sun Y, Han R. XRCC1 genetic polymorphisms and bladder cancer susceptibility: a meta-analysis. Urology. 2008;72:869–72.PubMedCrossRef
24.
Lao T, Gu W, Huang Q. A meta-analysis on XRCC1 R399Q and R194W polymorphisms, smoking and bladder cancer risk. Mutagenesis. 2008;23:523–32.PubMedCrossRef
25.
Lee CC, Yamamoto S, Morimura K, Wanibuchi H, Nishisaka N, et al. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer. 1997;79:780–9.PubMedCrossRef
26.
Hosokawa Y, Arnold A. Mechanism of cyclin d1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosomes Cancer. 1998;22:66–71.PubMedCrossRef
27.
Zhou P, Jiang W, Weghorst CM, Weinstein IB. Overexpression of cyclin D1 enhances gene amplification. Cancer Res. 1996;56:36–9.PubMed
28.
Sugasawa K, Shimizu Y, Iwai S, Hanaoka F. A molecular mechanism for DNA damage recognition by the xeroderma pigmentosum group C protein complex. DNA Repair (Amst). 2002;1:95–107.CrossRef
29.
Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23:257–64.PubMedCrossRef
30.
Chung CJ, Huang CJ, Pu YS, Su CT, Huang YK, et al. Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma. Toxicol Appl Pharmacol. 2008;232:203–9.PubMedCrossRef
31.
Lin HH, Ke HL, Hsiao KH, Tsai CW, Wu WJ, et al. Potential role of CCND1 G870A genotype as a predictor for urothelial carcinoma susceptibility and muscle-invasiveness in Taiwan. Chin J Physiol. 2011;54:196–202.PubMedCrossRef
32.
Garcia-Closas M, Malats N, Real FX, Welch R, Kogevinas M, et al. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:536–42.PubMedCrossRef
33.
Liu Y, Wang H, Lin T, Wei Q, Zhi Y, et al. Interactions between cigarette smoking and XPC-PAT genetic polymorphism enhance bladder cancer risk. Oncol Rep. 2012;28:337–45.PubMed
34.
35.
Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19:251–3.PubMedCrossRef
36.
37.
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676–80.PubMedCrossRef
38.
Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28:123–37.PubMedCrossRef
39.
Cortessis VK, Siegmund K, Xue S, Ross RK, Yu MC. A case–control study of cyclin D1 CCND1 870A → G polymorphism and bladder cancer. Carcinogenesis. 2003;24:1645–50.PubMedCrossRef
40.
Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–34.PubMedCrossRef
41.
Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis. 2005;26:1263–71.PubMedCrossRef
42.
Sak SC, Barrett JH, Paul AB, Bishop DT, Kiltie AE. Comprehensive analysis of 22 XPC polymorphisms and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:2537–41.PubMedCrossRef
43.
Wu X, Gu J, Grossman HB, Amos CI, Etzel C, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006;78:464–79.PubMedCentralPubMedCrossRef
44.
Zhu Y, Lai M, Yang H, Lin J, Huang M, et al. Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. Carcinogenesis. 2007;28:698–703.PubMedCrossRef
45.
Ye Y, Yang H, Grossman HB, Dinney C, Wu X, et al. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer. 2008;112:2467–74.PubMedCrossRef
46.
de Verdier PJ, Sanyal S, Bermejo JL, Steineck G, Hemminki K, et al. Genotypes, haplotypes and diplotypes of three XPC polymorphisms in urinary-bladder cancer patients. Mutat Res. 2010;694:39–44.PubMedCrossRef
47.
Gangwar R, Mittal RD. Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population. DNA Cell Biol. 2010;29:349–56.PubMedCrossRef
48.
Yuan L, Gu X, Shao J, Wang M, Zhu Q, et al. Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer. DNA Cell Biol. 2010;29:611–7.PubMedCrossRef
49.
Yuan L. Cyclin D1 polymorphism is associated with risk of bladder cancer in China. Nanjing: Nanjing Medical University; 2011.
50.
Liu Y. Interactions of XPC gene polymorphism with prostate cancer and bladder cancer risk in China. Chongqing: Third Military Medical University; 2012.
51.
Cohen LM, McCarthy DM, Brown SA, Myers MG. Negative affect combines with smoking outcome expectancies to predict smoking behavior over time. Psychol Addict Behav. 2002;16:91–7.PubMedCrossRef
52.
Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene–environment interactions. J Clin Oncol. 2000;18:2309–15.PubMed
53.
Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–30.PubMed
54.
Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000;89:630–9.PubMedCrossRef
55.
Metadata
Title
Association between CCND1 and XPC polymorphisms and bladder cancer risk: a meta-analysis based on 15 case–control studies
Authors
Yifei Wang
Zongping Li
Naibo Liu
Guan Zhang
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1412-9

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

Association of IL-6 polymorphisms with hepatocellular carcinoma risk: evidences from a meta-analysis

Research Article

Associations between polymorphisms of the XPC gene and lung cancer susceptibility: a meta-analysis

Research Article

The association of APE1 Asp148Glu gene polymorphisms and lung cancer risk: an updated meta-analysis

Research Article

Polymorphisms of Toll-like receptor 9 are associated with nasopharyngeal carcinoma susceptibility

Research Article

Knockdown of CD44 enhances chemosensitivity of acute myeloid leukemia cells to ADM and Ara-C

Research Article

Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits